0750 GMT - Novartis's 2025 guidance is constructive and beats consensus expectations, Intron Health analysts say in a note. The Swiss pharma giant's guidance is for mid-to-high single-digit sales growth, which is a 3% lift to consensus sales and EBIT, the analysts say. "Whilst we were worried about the impact of foreign-currency effects, Part D reform [U.S. Medicare drug pricing reform] and [multiple-sclerosis drug] Kesimpta pricing, this guidance looks very strong and appears higher than consensus," they say.(helena.smolak@wsj.com)

(END) Dow Jones Newswires

January 31, 2025 02:50 ET (07:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.